{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:19:54Z","timestamp":1792264794037,"version":"4.4.0"},"reference-count":38,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with relapsed\/refractory multiple myeloma (RRMM) have a high unmet treatment need. Belantamab mafodotin (belamaf), a first\u2010in\u2010class, B\u2010cell maturation antigen\u2010binding antibody\u2010drug conjugate, eliminates myeloma cells through direct cell killing and an anti\u2010myeloma immune response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DREAMM\u20102 (NCT03525678) was a phase 2, two\u2010arm, open\u2010label trial in patients with heavily pretreated RRMM who had three or more prior therapies, were refractory to an immunomodulatory agent and a proteasome inhibitor, and refractory or intolerant to an anti\u2010CD38 monoclonal antibody. Belamaf was given at 2.5 or 3.4\u00a0mg\/kg every 3\u00a0weeks. The primary end point was overall response rate (ORR); secondary end points included progression\u2010free survival (PFS), overall survival (OS), safety, ocular symptoms, and health\u2010related quality of life (HRQOL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This final analysis (cutoff date, March 31, 2022),\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a0223, with median follow\u2010up of 12.5 and 13.8\u00a0months, demonstrated an ORR of 32% and 35%, median PFS of 2.8 and 3.9\u00a0months, and median OS of 15.3 and 14.0\u00a0months in the 2.5\u00a0mg\/kg and 3.4\u00a0mg\/kg cohorts, respectively. Median duration of response was 12.5 and 6.2\u00a0months. No new safety signals were observed; the most common Grade 3 and 4 adverse events were keratopathy (29% vs. 25%), thrombocytopenia (22% vs. 29%), and anemia (21% vs. 28%). HRQOL outcomes suggest that overall global health status\/quality of life, physical and role functioning, and overall disease symptoms were maintained or improved during treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This final analysis of DREAMM\u20102 confirms that in patients with triple\u2010class refractory RRMM, single\u2010agent belamaf results in durable and clinically meaningful responses with a manageable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.34987","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:27:33Z","timestamp":1692952053000},"page":"3746-3760","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Single\u2010agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Final analysis of the DREAMM\u20102 trial"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"first","affiliation":[{"name":"Winship Cancer Institute Emory University Hospital  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-0188","authenticated-orcid":false,"given":"Ashraf","family":"Badros","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8781","authenticated-orcid":false,"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University Simon Cancer Center and Roudebush VAMC  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Callander","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center University of Wisconsin  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u2010Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"University of Kansas  Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward N.","family":"Libby","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"George Washington University  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Myeloma Service Department of Medicine Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg Medizinische Klinik II  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hakim","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lewis","sequence":"additional","affiliation":[{"name":"GSK  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Bhushan","sequence":"additional","affiliation":[{"name":"GSK  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"McKeown","sequence":"additional","affiliation":[{"name":"GSK  Stevenage UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"GSK  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Opalinska","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University Hospital  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00933\u20108"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2203478"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1903455"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100435\u20107"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30788\u20100"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201010\u2010535088"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.mct\u201021\u20100035"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u201000369\u20100"},{"key":"e_1_2_9_13_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03","year":"2009"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000494\u20104"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.58877\/japaj.v1i2.56"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010153443"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010171077"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.8060"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487\u2010022\u201000212\u20105"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024850"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112667"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010162709"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065303"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007923"},{"issue":"1","key":"e_1_2_9_27_1","first-page":"248","article-title":"No evidence of BCMA expression loss or systemic immune impairment after treatment with the BCMA\u2010targeted antibody\u2010drug conjugate (ADC) belantamab mafodotin (belamaf) in the DREAMM\u20101 and DREAMM\u20102 trials of patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Lowther DL","year":"2022","journal-title":"Blood"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123\u2010020\u201000280\u20108"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18298"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1613886"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00284\u20108"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.8019"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.8017"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000843604.69106.e8"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010147101"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010153315"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026251"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:40:06Z","timestamp":1760294406000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":38,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/cncr.34987"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34987","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"2023-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}